Semaglutide

GLP-1 support for appetite, weight, and metabolic care

Status

Available at launch

Mechanism

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It increases glucose-dependent insulin secretion, reduces glucagon signaling, slows gastric emptying, and lowers appetite through central satiety pathways. In weight-management protocols, those effects help reduce caloric intake while supporting steadier titration over time.

Indications

→Chronic weight-management support in eligible adults

→Appetite reduction and satiety support

→Metabolic care when lifestyle intervention alone has not been enough

→Long-term maintenance protocols under clinician supervision

Regulatory status

Branded semaglutide products are FDA-approved. Compounded semaglutide is not FDA-approved and should only be used when a patient's medical needs cannot be met by an available FDA-approved product and current compounding rules are satisfied. Northline's prescribing decisions are patient-specific and medically reviewed.

References

01FDA. WEGOVY (semaglutide) prescribing information.

02Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.